

Press release

AMOÉBA announces the availability of the 2022 Universal Registration Document including the Annual Financial Report

Lyon (France), April 18, 2023 -5.45 pm- AMOÉBA (FR0011051598 - ALMIB), an industrial biotech in pre-commercialization* specialized in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces that the 2022 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 18, 2023 under number D.23-0296.

The 2022 Universal Registration Document includes:

- the Annual Financial Report comprising the consolidated financial statements, the parent company financial statements, the management report and the related statutory auditors' reports
- the Board of Directors' corporate governance report.

The Universal Registration Document 2022 also presents the company's activities, particularly in the development of the biocidal and biocontrol applications and its research works. The organisation, financial situation, results and prospects of Amoéba are also described in the Document.

The document may be viewed or downloaded on the company's website www.amoeba-nature.com under section "Investors / financial documents/ Reference Document". Copies of the Universal Registration Document are also available at the company's headquarters: 38, avenue des frères Montgolfier, 69680 Chassieu, France.

Next event:

General Meeting of Shareholders: 25 May 2023

About AMOÉBA :

Amoéba's ambition is to become a major player in the treatment of microbiological risk in the water, plant protection and health sectors. Based on the natural properties of the amoeba *Willaertia magna* C2c Maky, our biological solution is a viable alternative to the chemical products widely used in the industry today. Amoeba is currently focused on the closed system industrial cooling tower market in the United States estimated at €200 million (1) and on the global biocontrol market for plant protection estimated at €3 billion (2), out of a global market for chemical fungicides estimated at €21 billion (3). The commercialization of the associated healthcare, biocides and phytosanitary products is subject to local regulatory approvals.

**At the end of 2022, Amoeba obtained approval of its active substance for biocidal use in closed cooling system and for biocontrol use in the United States. The substance has also been recommended for biocontrol use in Europe by the Austrian authority in the same year. The company is currently in a pre-commercialization phase*

for biocidal and plant protection applications and is expected to market its products by 2025. Founded in 2010 and based in Chassieu (Lyon, France), Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

(1): Amoéba data

(2): IBMA Source

(3): Amoeba data

Contacts :

Amoéba

Valérie FILIATRE

Deputy General Manager



+33 4 26 69 16 00



v.filiatre@amoeba-nature.com

Calyptus

Investor & Press Relations

Nicolas HELIN / Mathieu CALLEUX



+33 1 53 65 37 90 /91



amoeba@calyptus.net